Co-Authors
This is a "connection" page, showing publications co-authored by JENNIFER WARGO and JENNIFER LEIGH MCQUADE.
Connection Strength
3.831
-
Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers. Curr Oncol Rep. 2020 06 24; 22(7):74.
Score: 0.733
-
Modulating the microbiome to improve therapeutic response in cancer. Lancet Oncol. 2019 02; 20(2):e77-e91.
Score: 0.665
-
Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy. BMC Cancer. 2024 Dec 04; 24(1):1493.
Score: 0.249
-
Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. Clin Cancer Res. 2023 01 04; 29(1):154-164.
Score: 0.218
-
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2023 Jan; 613(7945):E3.
Score: 0.218
-
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640.
Score: 0.203
-
Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers (Basel). 2021 Oct 22; 13(21).
Score: 0.201
-
Gut Microbiome Modulates Response to Cancer Immunotherapy. Dig Dis Sci. 2020 03; 65(3):885-896.
Score: 0.179
-
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.
Score: 0.156
-
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
Score: 0.155
-
Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2024 Jun; 30(6):1787.
Score: 0.060
-
Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial. EBioMedicine. 2023 Dec; 98:104873.
Score: 0.058
-
Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma. JAMA Dermatol. 2023 10 01; 159(10):1076-1084.
Score: 0.057
-
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Ann Oncol. 2023 09; 34(9):796-805.
Score: 0.056
-
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023 04; 29(4):898-905.
Score: 0.055
-
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2023 Mar; 615(7953):E23.
Score: 0.055
-
Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022 11; 611(7934):155-160.
Score: 0.054
-
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.
Score: 0.053
-
Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. J Invest Dermatol. 2022 07; 142(7):2046-2049.e3.
Score: 0.051
-
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.
Score: 0.049
-
Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol. 2020 05 01; 38(13):1429-1441.
Score: 0.045
-
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov. 2019 05; 9(5):628-645.
Score: 0.042
-
A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov. 2018 05; 8(5):556-567.
Score: 0.039
-
Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology. 2017; 6(12):e1361097.
Score: 0.038
-
Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. J Invest Dermatol. 2017 08; 137(8):1792-1795.
Score: 0.037
-
Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer. 2017 04 15; 123(8):1372-1381.
Score: 0.036
-
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016 Aug 01; 2(8):1056-64.
Score: 0.035
-
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
Score: 0.033